Javascript must be enabled to continue!
Clinical, Immunological and Molecular Findings of Patients with Severe Combined Immunodeficiency: Introducing of 7 Novel Mutations in 7 Genes
View through CrossRef
Abstract
Purpose
Severe combined immunodeficiency (SCID) is one of the severe inborn errors of the immune system associated with life-threatening infections. This disorder is characterized by diminished cellular and humoral immunity. A variable phenotype, including atypical and leaky SCID cases, as well as the heterogeneity in its genetic basis, may lead to a significant delay in diagnosis. Therefore, early diagnosis of SCID patients is crucial. Here, we describe the clinical manifestations and genetic results of four patients with SCID and four patients with atypical SCID.
Methods
Eight patients, who were clinically suspected to SCID, underwent immunological evaluations and genetic studies. Whole Exome Sequencing (WES) was used to identify the most relevant genetic defects which are responsible for the patients’ clinical phenotype. Further, the identified mutations were evaluated by Sanger sequencing in patients and their parents.
Results
All patients (4 males and 4 females) presented SCID phenotype in early infancy within 6 months of life. We found eight mutations, including two novel mutations in RAG2 (p.I273T, p.G44X), a novel 2-bp deletion in IL7R (p.F361WfsX17), a novel 2-bp deletion in LAT (p.Y207fs), a novel mutation in ADA (c.780 + 1G > A), a novel mutation in JAK3 (p.Q228Ter), a novel mutation in LIG4 (p.G428R), and also a previously reported missense mutation in RAG1 (p.A444V). All patients were homozygous, and their parents were heterozygous.
Conclusion
The results of our study expand the clinical and molecular spectrum associated with SCID and leaky SCID phenotypes and provide valuable information for the clinical management of our patients.
Springer Science and Business Media LLC
Zahra Alizadeh
Mohammad Reza Fazlollahi
Marzieh Mazinani
Mohsen Badalzadeh
Hanieh Heydarlou
Raphael Carapito
Anne Molitor
Andrés Caballero Garcia de Oteyza
Michele Proietti
Maryam Soleimani bavani
Mansoureh Shariat
Morteza Fallahpour
Masoud Movahedi
Leila Moradi
Bodo Grimbacher
Siamak Bahram
Zahra Pourpak
Title: Clinical, Immunological and Molecular Findings of Patients with Severe Combined Immunodeficiency: Introducing of 7 Novel Mutations in 7 Genes
Description:
Abstract
Purpose
Severe combined immunodeficiency (SCID) is one of the severe inborn errors of the immune system associated with life-threatening infections.
This disorder is characterized by diminished cellular and humoral immunity.
A variable phenotype, including atypical and leaky SCID cases, as well as the heterogeneity in its genetic basis, may lead to a significant delay in diagnosis.
Therefore, early diagnosis of SCID patients is crucial.
Here, we describe the clinical manifestations and genetic results of four patients with SCID and four patients with atypical SCID.
Methods
Eight patients, who were clinically suspected to SCID, underwent immunological evaluations and genetic studies.
Whole Exome Sequencing (WES) was used to identify the most relevant genetic defects which are responsible for the patients’ clinical phenotype.
Further, the identified mutations were evaluated by Sanger sequencing in patients and their parents.
Results
All patients (4 males and 4 females) presented SCID phenotype in early infancy within 6 months of life.
We found eight mutations, including two novel mutations in RAG2 (p.
I273T, p.
G44X), a novel 2-bp deletion in IL7R (p.
F361WfsX17), a novel 2-bp deletion in LAT (p.
Y207fs), a novel mutation in ADA (c.
780 + 1G > A), a novel mutation in JAK3 (p.
Q228Ter), a novel mutation in LIG4 (p.
G428R), and also a previously reported missense mutation in RAG1 (p.
A444V).
All patients were homozygous, and their parents were heterozygous.
Conclusion
The results of our study expand the clinical and molecular spectrum associated with SCID and leaky SCID phenotypes and provide valuable information for the clinical management of our patients.
Related Results
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia
Abstract
Introduction. Ultra-deep next generation sequencing (NGS) allows sensitive detection of mutations and estimation of their clonal abundance in tumor cell pop...
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Abstract
Introduction
Higher-risk myelodysplastic syndromes (MDS) progress to secondary acute myeloid leukemia (sAML) within mon...
Categorizing Molecular Mutations in MDS and AML
Categorizing Molecular Mutations in MDS and AML
Abstract
Introduction:
A huge amount of data on genetic alterations has been compiled by high throughput sequencing studies in several hematologic mal...
Distinct Profile of FLT3 Mutations in Brazil.
Distinct Profile of FLT3 Mutations in Brazil.
Abstract
Mutations in the tyrosine kinase receptor FLT3 are the most common molecular abnormality in acute myeloid leukemia (AML) being detected in about 30% of AML ...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
Introduction: The activated B-cell-like (ABC) molecular subgroup of diffuse large B-cell lymphoma (DLBCL) is characterized by activation of NF-κB signaling and increased mortality....

